Go Pro

Roivant Sciences (ROIV) 10K Form and Latest SEC Filings 2026

Roivant Sciences logo
$37.11 -0.29 (-0.78%)
As of 11:51 AM Eastern

Latest Roivant Sciences SEC Filings & Recent Activity

Roivant Sciences (NASDAQ:ROIV) has submitted 754+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Roivant Sciences's financial statements. The most recent filing was a Form 4 submitted on August 18, 2026.

Form 4
Roivant Sciences Ltd. Reports Ownership Change on Aug. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Roivant Sciences Files Current Report on Aug. 6, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Roivant Sciences Files Quarterly Report on Aug. 6, 2026

The 10-Q contains Roivant Sciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Roivant Sciences SEC Filing History

Browse Roivant Sciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/18/2026 8:00 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2026 3:29 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/17/2026 3:40 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 2:45 PM
MORGAN STANLEY (895421) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
08/06/2026 6:28 AM
Roivant Sciences (1635088) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/06/2026 6:13 AM
Roivant Sciences (1635088) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2026 8:00 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2026 8:00 PM
Oren Ilan (1643073) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2026 8:00 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2026 8:00 PM
MOMTAZEE JAMES C (1209181) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 6:00 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 6:01 PM
Roivant Sciences (1635088) Issuer
Torti Frank (1647805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 6:03 PM
Fitzgerald Meghan (1349297) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 6:06 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2026 5:34 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2026 7:38 PM
MANCHESTER KEITH S (1244828) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2026 7:30 PM
Gold Daniel Allen (1832142) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2026 6:59 PM
QVT Financial LP (1290162) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2026 3:36 PM
Fitzgerald Meghan (1349297) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 5:23 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2026 3:40 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 5:13 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2026 3:33 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 3:01 PM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/23/2026 8:16 PM
Humes Jennifer (2058012) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2026 8:17 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2026 5:25 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2026 5:22 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2026 3:40 PM
Roivant Sciences (1635088) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/20/2026 6:14 AM
Roivant Sciences (1635088) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2026 6:17 AM
Roivant Sciences (1635088) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
05/12/2026 12:19 PM
MORGAN STANLEY (895421) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
05/06/2026 8:07 PM
Ramaswamy Vivek (1635075) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
04/22/2026 5:26 PM
Humes Jennifer (2058012) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:26 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:27 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 8:00 PM
Oren Ilan (1643073) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 5:32 PM
MOMTAZEE JAMES C (1209181) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 5:34 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 5:27 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 3:17 PM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Buffett's Final Warning: "The Dollar Is Going to Hell" (Ad)

The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defense budget. There's no way to tax our way out. No way to cut our way out. The government has exactly one move left: Pump trillions into AI to outgrow the debt. And the asset class profiting from these trillions in spending. BlackRock is buying. Goldman Sachs is buying. Gartner is calling it the next decade defining boom. The last time a similar setup formed, early investors saw gains of up to 12,480%. I've put together a workshop breaking this down in detail. I'll name the asset class and show you exactly how to profit from this $39 trillion debt crisis.tc pixel

Click here to register for the free workshop →
04/16/2026 4:24 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Subject
Form 144/A
04/16/2026 3:33 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2026 5:00 PM
Humes Jennifer (2058012) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 3:07 PM
Humes Jennifer (2058012) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/02/2026 6:14 PM
Roivant Sciences (1635088) Issuer
Torti Frank (1647805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 6:00 AM
Roivant Sciences (1635088) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2026 6:19 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 6:20 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/30/2026 8:01 PM
Fitzgerald Meghan (1349297) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 3:14 PM
Fitzgerald Meghan (1349297) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/24/2026 6:07 PM
Humes Jennifer (2058012) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2026 6:08 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 7:44 AM
Roivant Sciences (1635088) Filer
Form 8-K/A
03/19/2026 5:36 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 5:23 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 3:17 PM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 3:04 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2026 9:05 AM
FMR LLC (315066) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
03/03/2026 6:13 AM
Roivant Sciences (1635088) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2026 5:43 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 5:43 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 7:40 PM
Roivant Sciences (1635088) Issuer
Torti Frank (1647805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:24 PM
Roivant Sciences (1635088) Subject
Torti Frank (1647805) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 4:57 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 8:00 PM
Gold Daniel Allen (1832142) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 8:02 PM
MANCHESTER KEITH S (1244828) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 7:45 PM
QVT Financial LP (1290162) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 2:32 PM
Ramaswamy Vivek (1635075) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
02/11/2026 4:53 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/11/2026 10:50 AM
MORGAN STANLEY (895421) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
02/06/2026 6:31 AM
Roivant Sciences (1635088) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
02/06/2026 6:12 AM
Roivant Sciences (1635088) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2026 12:36 PM
FMR LLC (315066) Filed by
Roivant Sciences (1635088) Subject
Form SCHEDULE 13G/A
01/22/2026 8:00 PM
Epperly Melissa B, (1807359) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:00 PM
Oren Ilan (1643073) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:00 PM
MOMTAZEE JAMES C (1209181) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 8:00 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:04 PM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/31/2025 8:00 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2025 3:30 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 8:00 PM
Roivant Sciences (1635088) Issuer
Venker Eric (1801917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 8:00 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 8:00 PM
Roivant Sciences (1635088) Issuer
Torti Frank (1647805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:31 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 8:36 AM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 8:05 AM
Roivant Sciences (1635088) Subject
Torti Frank (1647805) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2025 8:00 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:19 PM
Pulik Richard (1885841) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2025 3:04 PM
Roivant Sciences (1635088) Subject
Venker Eric (1801917) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 8:04 PM
Roivant Sciences (1635088) Issuer
Sukhatme Mayukh (1750050) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
12/18/2025 6:52 PM
MANCHESTER KEITH S (1244828) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 6:54 PM
Gold Daniel Allen (1832142) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 6:41 PM
QVT Financial LP (1290162) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 8:00 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 4:09 PM
Roivant Sciences (1635088) Subject
Sukhatme Mayukh (1750050) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/15/2025 8:34 PM
Ramaswamy Vivek (1635075) Reporting
Roivant Sciences (1635088) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 4:13 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Subject
Form 144/A
12/15/2025 3:36 PM
Gline Matthew (1750094) Reporting
Roivant Sciences (1635088) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/12/2025 4:20 PM
Immunovant, Inc. (1764013) Subject
Roivant Sciences (1635088) Filed by
Form SCHEDULE 13D/A
(Data available from 1/1/2016 forward)

Roivant Sciences SEC Filings - Frequently Asked Questions

Roivant Sciences (ROIV) has submitted 754+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Roivant Sciences's fiscal year ends on March 31. The company typically files its 10-K annual report by the end of May, covering the prior fiscal year's financial results. Key financial data from these reports is available on Roivant Sciences's financial statements page.

The most recent filing was a Form 4 submitted on August 18, 2026. This was an insider ownership change filed by 4 - Roivant Sciences Ltd. (0001635088) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ROIV) was last updated on 8/20/2026 by MarketBeat.com Staff.
From Our Partners